Enlicitide Chloride

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HealthyHypercholesterolemiaModerate Renal Impairment

Phase 1

A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)

CompletedNCT05070390

Merck Sharp & Dohme LLCModerate Renal Impairment

Start: 2021-11-16End: 2023-05-03Updated: 2026-08-19

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

CompletedNCT06655311

Merck Sharp & Dohme LLCHealthy, Hypercholesterolemia

Start: 2022-09-30End: 2024-01-02Updated: 2024-10-23

A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)

CompletedNCT06814106

Merck Sharp & Dohme LLCHealthy

Start: 2023-03-06End: 2023-05-08Updated: 2025-02-07